Soluble Fms-Like Tyrosin Kinase-1 and Placental Growth Factor Biomarkers Integrated for Predictability of Preeclampsia

Mahmoud Abosrea*, Ahmed Mousad* and Asmaa Elfallah **

*Department of Obstetrics & Gynaecology, Faculty of Medicine, Benha University, Benha. Egypt.
**Department of clinical pathology, Faculty of Medicine, Benha University, Benha. Egypt.

Submission: September 10, 2019, Published: September 18, 2019

*Corresponding author: Mahmoud Abosrea, Department of Obstetrics & Gynaecology, Benha University, Egypt

Abstract

**Background:** Biomarkers in diagnostic and prognostic approaches in obstetric research efforts are gaining a global interest however the sensitivity and specificity of those biomarkers are considered an issue of research debate

**Aim:** To investigate usefulness and reliability of implementing the usage of sFlt-1/PIGF ratio for predictability of the presence or absence of preeclampsia development.

**Methodology:** A cohort and randomized research study was conducted on 50 pregnant cases, the course of pregnancy was observed extensively in randomly selected pregnant women. Personal and history data, personal habits, the course and pregnancy clinical outcome was recorded. Research study subjects were equally categorized in two groups as follows: the control group and the preeclampsia group. Serum levels of sFlt-1 and PIGF in obtained samples was determined retrospectively by usage of Elecsys assays on an electrochemiluminescence immunoassay platform and implemented to calculate the sFlt-1/PIGF ratio.

**Result:** Comparative statistical analysis of soluble fms-like tyrosine kinase 1, placental growth factor and sFLT/PlGF ratio among term and preterm preeclampsia cases showed highly statistical significant difference between term and preterm research categories of preeclampsia cases as regards soluble fms-like tyrosine kinase 1 (pg/ml) 24-28 GA, 28-31 GA (p values <0.001), besides there was statistical significant difference as regards PlGF (pg/ml) 24-28 GA, PlGF (pg/ml) 28-32 GA (p values =0.021,0.011 consecutively).

**Conclusion:** Angiogenic factors are cornerstone biomarkers that could be applied as a predictability tool for preeclampsia particularly when integrated in the form of ratio.

Introduction

Preeclampsia is a multisystem disease and is one of the frequently presented clinical scenarios in every day obstetric practice. Researchers all over the globe are frequently trying to innovatively advance the diagnostic and therapeutic protocols to enhance the level of management of this obstetric issue [1,2]. Preeclampsia as a heterogeneous disorder it impacts in a negative manner the physiological balances at both maternal and fetal levels that causes in some cases a serious threat on maternal and neonatal lives and is a highly complex disease in its pathophysiological nature with various risk factors that interplay in its development [3,4]. Biomarkers in diagnostic and prognostic approaches in obstetric research efforts are gaining a global interest however the sensitivity and specificity of those biomarkers are considered an issue of research debate. pathological and clinical courses of preeclampsia are highly variable and are considered highly challenging in some situations as mild forms of the disease could be suddenly progressive within a short period of time causing prematurity and morbid maternal issues such as post-partum hemorrhage [5,6].

Correlated hematological affection are considered one of the lethal sequelae of preeclampsia if not properly managed such as HELLP syndrome, end organ damage particularly in cases with severe proteinuria and CNS symptoms denoting rapid progression of the disease [7,8]. Preeclampsia could develop denovo or on top of hypertensive disorders preexisting before conception and could develop on top of gestational hypertension, maternal, fetal and placental factors interplay in the complex pathological development of the disease which raised the interest to investigate the possible biomarkers that could be assayed aiding in detectability of abnormal changes in serum levels. Abnormal
placental vascular remodeling and changes could be the cornerstone issue that if investigated could elucidate the pathophysiological roots of the disease development since placental hypo-perfusion is one of the real challenges to the obstetrician in disease management and decision making [9,10].

Endothelial dysfunction is revealed and displayed by various research groups to be the cornerstone issue in triggering the disease development course such as placental growth factor (PIGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) circulating angiogenic factors. Angiogenic factors secreted by the placenta are the cornerstone regulators of placental vascular system performance [11,12]. High fms-like tyrosine kinase-1 serum levels (anti-angiogenic protein) and low placental growth factor serum levels (pro-angiogenic protein), are highly reliable biomarkers for consecutive pathological development of preeclampsia. However, the exact cutoff values are an issue of research debate and the current clinical profile and routine investigative tools are highly variable and require support by more early investigative tools for early prediction of disease development [13,14].

Aim of the Work

To investigate usefulness and reliability of implementing the usage of sFlt-1/PIGF ratio for predictability of the presence or absence of preeclampsia development.

Methodology

This cohort and randomized research study were performed on a total of 50 pregnant cases recruited from the Department of Gynecology and Obstetrics in Benha University Hospital during a period from May 2018 to April 2019. We had ethical approval for this study protocol from Benha Faculty of Medicine ethical committee; also, all included participants signed full informed written consents. The course of pregnancy was observed extensively in randomly selected pregnant women. Personal and history data, personal habits, the course and pregnancy clinical outcome was recorded. Cases were presented with and signed an informed written consent. Research study subjects were equally categorized in two research groups as follows the control research group and the preeclampsia research group.

The control research group involved cases that are normotensive and no proteinuria all the way through gestation. The diastolic blood pressure ≥90mm Hg after 20th gestational weeks As regard the features of the research study cohort at time of delivery were presented as median with inter-quartile range (IQR) and compared using Mann-Whitney test between two groups. Also, the comparison regarding qualitative variables was done by using Chi-square test and/or Fisher exact test when the expected count was found less than 5 in any cell. The confidence interval was set to 95% and the margin of error accepted was set to 5%. So, the p-value was considered significant at the level of < 0.05.

Table 1: Demographic and clinical characteristics of the research groups (control and PE).

<table>
<thead>
<tr>
<th>Control Group No. = 25</th>
<th>PE Group No. = 25</th>
<th>Test Value</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>29.35±4.3</td>
<td>30.45±2</td>
<td>0.778*</td>
<td>0.44</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>26.3±4.2</td>
<td>28.46±3</td>
<td>1.387*</td>
<td>0.172</td>
</tr>
<tr>
<td>Nullipara (40.0%)</td>
<td>11 (44.0%)</td>
<td></td>
<td>0.082*</td>
<td>0.774</td>
</tr>
</tbody>
</table>

Sampling

5 milliliters of venous blood were withdrawn from each subject and collected in serum separating tubes. Clotted samples were centrifuged within one hour of sampling at 3000rpm for 10 minutes. The serum was then separated and kept in eppendorf tubes and stored at -20 °C till time of assay. Serum levels of sFlt-1 and PIGF in obtained samples were determined retrospectively by usage of Elecsys assays on an electrochemiluminescence immunoassay platform (Cobase analyzer, Roche Diagnostik, Germany) and implemented to calculate the sFlt-1/PIGF ratio.

Statistical Analysis

Data were collected, revised, coded and entered to the Statistical Package for Social Science (IBM SPSS) version 23. Data were checked for normality using Kolmogorov-Smirnov test and the quantitative data with parametric distribution were presented as mean, standard deviations and ranges and compared using independent t-test between two groups and One Way ANOVA between more than two groups while with non parametric distribution were presented as median with inter-quartile range (IQR) and compared using Mann-Whitney test between two groups. Also, the comparison regarding qualitative variables was done by using Chi-square test and/or Fisher exact test when the expected count was found less than 5 in any cell. The confidence interval was set to 95% and the margin of error accepted was set to 5%. So, the p-value was considered significant at the level of < 0.05.

Result

The demographic and clinical features of the research study groups recruited was displayed in Table 1 in which there was no statistical significant difference as regards age, BMI, nullipara, Gestational age (weeks), 2nd trimester, Gestational age (weeks), 3rd trimester, current smokers, chronic disease, drugs, family history of PE, PE in previous pregnancies, GDM in previous pregnancies (p values =0.440, 0.172, 0.774, 0.875, 0.783, 0.712, 0.384, 0.349, 0.508, 0.122, 0.551 consecutively) Among the cohort of 50 patients 25 patients developed clinical preeclampsia: 15 before 37 gestational weeks and 10 after 37 gestational weeks. As regard the features of the research study cohort at time of delivery there was a highly statistical significant difference between control research group and preeclampsia developing after and before 37 gestational weeks as regards IUGR development, APGAR score, birth weight, gestational age weeks, mode of delivery (p values =0.001, <0.001, <0.001, <0.001, <0.001 consecutively) Table 2.
### Table 2: Features of the research study cohort at time of delivery.

<table>
<thead>
<tr>
<th>Control Group No. = 25</th>
<th>PE &gt; 37 GA No. = 15</th>
<th>PE &lt; 37 GA No. = 10</th>
<th>Test Value</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUGR</td>
<td>0 (0.0%)</td>
<td>3 (20.0%)</td>
<td>5 (50.0%)</td>
<td>13.542*</td>
<td>0.001 HS</td>
</tr>
<tr>
<td>Apgar score</td>
<td>10 (8 - 10)</td>
<td>9 (7 – 10)</td>
<td>7 (5 – 8)</td>
<td>3.812*</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>Birth weight</td>
<td>3512±215</td>
<td>3125±250</td>
<td>2730±218</td>
<td>45.292*</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>39.3±1.3</td>
<td>38.6±0.9</td>
<td>32.1±2.1</td>
<td>99.969•</td>
<td>&lt; 0.001 HS</td>
</tr>
<tr>
<td>Mode of delivery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NVD</td>
<td>20 (80.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS</td>
<td>5 (20.0%)</td>
<td>15 (100.0%)</td>
<td>10 (100.0%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*: Data were presented as numbers and percentages and compared using Chi-square test
•: Data were presented as mean ± SD and compared using independent t-test
≠: Data were presented as median with interquartile range (IQR) and compared using Kruskal-Wallis test.

### Table 3: Maternal serum levels of soluble fms-like tyrosine kinase 1 (sFLT), placental growth factor (PlGF) and sFLT/PlGF ratio in cases with preeclampsia and matched research controls.

<table>
<thead>
<tr>
<th></th>
<th>Control Group</th>
<th>PE Group</th>
<th>Test Value</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>sFLT (pg/ml) 24-28 GA</td>
<td>1409 (415.35 – 2541)</td>
<td>2130 (560.3 – 4863)</td>
<td>5.612</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
<tr>
<td>sFLT (pg/ml) 28-31 GA</td>
<td>1519 (495 – 2842)</td>
<td>3137 (498.5 – 6513)</td>
<td>9.124</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
<tr>
<td>PI GF (pg/ml) 24-28 GA</td>
<td>521 (210 – 2031)</td>
<td>198 (35.4 – 418.3)</td>
<td>4.812</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
<tr>
<td>PI GF (pg/ml) 28-32 GA</td>
<td>585.3 (240 – 2320)</td>
<td>147.5 (23.8 – 385)</td>
<td>8.614</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
<tr>
<td>sFLT/PlGF 24-28</td>
<td>2.41 (1.3 – 6.45)</td>
<td>8.86 (1.95 – 98.6)</td>
<td>7.315</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
<tr>
<td>sFLT/PlGF 28-31</td>
<td>2.125 (0.713 – 9.73)</td>
<td>15.35 (0.612 – 117.3)</td>
<td>8.647</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
</tbody>
</table>

*: Data were presented as median with interquartile range (IQR) and compared using Mann-Whitney test
≠: Data were presented as mean ± SD and compared using One Way ANOVA

### Table 4: Comparative statistical analysis of soluble fms-like tyrosine kinase 1 (sFLT), placental growth factor (PI GF) and sFLT/PI GF ratio among term and preterm preeclampsia cases.

<table>
<thead>
<tr>
<th></th>
<th>PE &gt; 37 GA No. = 15</th>
<th>PE &lt; 37 GA No. = 10</th>
<th>Test Value</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>sFLT (pg/ml) 24-28 GA</td>
<td>827.6 (352.8 – 2670)</td>
<td>2870 (780 – 4863)</td>
<td>6.254</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
<tr>
<td>sFLT (pg/ml) 28-31 GA</td>
<td>925.4 (385.6 – 2412)</td>
<td>4203 (1098.6 – 6513)</td>
<td>9.314</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
<tr>
<td>PI GF (pg/ml) 24-28 GA</td>
<td>215 (135.6 – 418.3)</td>
<td>67.9 (35.4 – 198.4)</td>
<td>3.879</td>
<td>0.021 S</td>
<td></td>
</tr>
<tr>
<td>PI GF (pg/ml) 28-32 GA</td>
<td>187.6 (121.0 – 385)</td>
<td>56.9 (23.8 – 137.2)</td>
<td>4.219</td>
<td>0.011 S</td>
<td></td>
</tr>
<tr>
<td>sFLT/PlGF 24-28</td>
<td>2.315 (1.95 – 10.971)</td>
<td>35.7 (27.25 – 98.6)</td>
<td>9.138</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
<tr>
<td>sFLT/PlGF 28-31</td>
<td>4.314 (0.612 – 3.12)</td>
<td>86.4 (37.6 – 117.3)</td>
<td>7.145</td>
<td>&lt;0.001 HS</td>
<td></td>
</tr>
</tbody>
</table>

*: Data were presented as median with interquartile range (IQR) and compared using Mann-Whitney test
≠: Data were presented as numbers and percentages and compared using Chi-square test
•: Data were presented as mean ± SD and compared using independent t-test
≠: Data were presented as median with interquartile range (IQR) and compared using Mann-Whitney test
Statistical comparative analysis of maternal serum levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PIGF) and sFlt1/PIGF ratio in cases with preeclampsia and matched research controls showed that there was a highly statistical significant difference as regards sFlt1 (pg/ml) 24-28 GA, sFlt1 (pg/ml) 28-31 GA, PIGF (pg/ml) 24-28 GA, PIGF (pg/ml) 28-32 GA, sFlt1/PIGF 24-28 gestational age, sFlt1/PIGF 28-31 gestational age (p values <0.001) Table 3. The Comparative statistical analysis of soluble fms-like tyrosine kinase 1, placental growth factor and sFlt1/PIGF ratio among term and preterm pre-eclampsia cases revealed a highly statistical significant difference between term and preterm research categories of preeclampsia cases as regards soluble fms-like tyrosine kinase 1 (pg/ml) 24-28 GA, 28-31 GA (p values <0.001), besides there was statistical significant difference as regards PIGF (pg/ml) 24-28 GA, PIGF (pg/ml) 28-32 GA (p values =0.021,0.011 consecutively) Table 4.

Discussion

Preeclampsia is a common clinical scenario in obstetric every day practice and is well known as the disease of theories prior research groups of investigators support the theory that preeclampsia pathophysiological development course results from serum levels disproportion of placentatic angiogenic and antiangiogenic factors that negatively influence maternal vascular endothelial surface functional performance at molecular, cellular and physiologic levels, causing the maternal and fetal characteristics observed in those clinical scenarios, previous studies similar to the current research study in approach and methodology showed that serum levels of sFlt-1 have been statistically significantly higher and PIGF significantly lower in cases that pathologically developed preeclampsia in comparison to cases that had a normal gestational clinical outcome [15].

The aim of using the sFlt-1 and PIGF biomarkers is to identify high-risk pregnant women who require intensive monitoring, and to rule out PE onset so avoiding unnecessary hospitalization. Furthermore, prior investigators have shown among their research studies that the ratio of sFlt-1 to PIGF have been statistically significantly higher in cases that pathologically developed preeclampsia in comparison to cases that had a normal gestational outcome [1,6,10]. In an interesting manner prior research showed among their characteristics observed in those clinical scenarios, previous studies similar to the current research study in approach and methodology showed that serum levels of sFlt-1 have been statistically significantly higher and PIGF significantly lower in cases that pathologically developed preeclampsia in comparison to cases that had a normal gestational clinical outcome [15].

The author declared that they have no conflict of interest regarding this article.

References


Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php